Goldman Sachs Group, Inc. (The) set a €72.00 ($83.72) price objective on MorphoSys AG (ETR:MOR) in a report published on Wednesday morning. The firm currently has a neutral rating on the stock.

Several other research analysts have also recently commented on MOR. Commerzbank Ag set a €76.00 ($88.37) price target on MorphoSys AG and gave the stock a buy rating in a research note on Tuesday, November 7th. Independent Research GmbH set a €93.00 ($108.14) price target on MorphoSys AG and gave the stock a buy rating in a research note on Tuesday, November 7th. Berenberg Bank set a €85.00 ($98.84) price target on MorphoSys AG and gave the stock a buy rating in a research note on Tuesday, November 7th. J P Morgan Chase & Co set a €85.00 ($98.84) price target on MorphoSys AG and gave the stock a buy rating in a research note on Wednesday. Finally, Deutsche Bank AG set a €90.00 ($104.65) price target on MorphoSys AG and gave the stock a buy rating in a research note on Monday, August 7th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. MorphoSys AG currently has a consensus rating of Buy and an average price target of €81.25 ($94.48).

MorphoSys AG (ETR MOR) opened at €76.54 ($89.00) on Wednesday. MorphoSys AG has a one year low of €38.14 ($44.35) and a one year high of €82.13 ($95.50).

TRADEMARK VIOLATION WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.watchlistnews.com/morphosys-ag-mor-given-a-72-00-price-target-at-goldman-sachs-group-inc-the/1697528.html.

MorphoSys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with Analyst Ratings Network's FREE daily email newsletter.